GHTC delivers statement on GSPOA at HHS WHA listening session
GHTC delivered the following statement, on the 74th World Health Assembly (WHA) agenda item 13.4, global strategy and plan of action on public health, innovation, and intellectual property (GSPOA), on May 13, 2021 at the US Department of Health and Human Services (HHS) WHA stakeholder listening session:
The Global Health Technologies Coalition appreciates the opportunity to comment on the global strategy and plan of action on public health, innovation and intellectual property (GSPOA) ahead of the World Health Assembly.
As outlined in the WHO review panel’s report, although progress has been made in certain aspects of both innovation and access, many of the challenges that motivated formulation of the GSPOA remain, and the COVID-19 pandemic has exposed both long-standing shortcomings as well as new challenges. These include a lack of new health products in areas of need, the unaffordability of many new medicines and
GHTC delivers statement on AMR at HHS WHA listening session
GHTC delivered the following statement, on the 74th World Health Assembly (WHA) agenda item 13.5, antimicrobial resistance (AMR), on May 13, 2021 at the US Department of Health and Human Services (HHS) WHA stakeholder listening session:
The Global Health Technologies Coalition appreciates the opportunity to comment on the antimicrobial resistance agenda item ahead of the World Health Assembly.
The pandemic has exacerbated the fight against AMR, as COVID-19 and other competing global priorities are reducing activities aimed to address AMR while increasing the use of antibiotics. Secondary infections further complicate treatment for patients with COVID-19, particularly those with severe illness. Health services including treatment and immunization campaigns have been disrupted, research and clinical trials have stalled, and investments have been reallocated. This has increased the risk of greater antimicrobial misuse and
Powering Vaccine R&D: A Discussion on the Future of the Global Ecosystem for Vaccine R&D
The rapid development of COVID-19 vaccines is fueling a reimagining of what is possible for vaccine research and development (R&D). Join us for a panel discussion and Q&A reflecting on ideas offered in a forthcoming report by the Sabin-Aspen Vaccine Science & Policy Group, Powering Vaccine R&D: Opportunities for Transformation. This report will draw on historic lessons learned from vaccine development to outline opportunities to overhaul vaccine R&D practices to better prepare for the next pandemic, to make strides against diseases currently without vaccines, and to establish next-generation vaccines that offer meaningful improvements. Expert panelists will reflect on what it will take to transform the vaccine R&D ecosystem and how stakeholders at all levels can help support those efforts.
ASM joined partners in submitting the following request to Congress.
Dear Chairman Leahy, Vice Chairman Shelby, Chair Murray and Ranking Member Blunt
cc: Chair DeLauro, Ranking Member Granger and Ranking Member Cole:
We, the undersigned organizations, respectfully request that you provide $60 million for the Advanced Molecular Detection (AMD) program at the Centers for Disease Control and Prevention (CDC) in the Fiscal Year (FY) 2022 Labor, Health and Human Services, Education and Related Agencies bill. The AMD program uses next generation sequencing (NGS) to bring the concept of precision medicine to bear for “precision public health.”
AMD gives us new tools to detect disease faster, identify outbreaks sooner, and protect people from emerging and evolving disease threats. It informs vaccine development, helps identify and track antimicrobial resistance and foodborne illness, and informs the development of diagnostics for new, existing and emerging diseases. AMD has played a
Study: U S Congress has clear opportunity to supercharge global health R&D, shows report news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.